| Characteristics . | Overall (n = 44) . | Malawi (n = 30) . | South Africa (n = 8) . | Tanzania (n = 5) . | Thailand (n = 1) . |
|---|---|---|---|---|---|
| Age, median | 39 | 38.5 | 40.5 | 39 | 44 |
| Female, % | 66.0 | 74.0 | 62.5 | 40 | 0.0 |
| VL median, log copies/mL | 4.75 | 5.01 | 4.26 | 5.01 | 4.29 |
| CD4 median, cells/µL | 115 | 56 | 209 | 172 | 6 |
| First-line regimen | |||||
| d4T 3TC EFV | 5 | 0 | 5 | 0 | 0 |
| d4T 3TC NVP | 25 | 17 | 2 | 5 | 1 |
| TDF 3TC NVP | 3 | 3 | 0 | 0 | 0 |
| AZT 3TC EFV | 1 | 0 | 1 | 0 | 0 |
| AZT 3TC NVP | 10 | 10 | 0 | 0 | 0 |
| Time median on first-line, months | 36 | 39 | 22 | 54 | 32 |
| Characteristics . | Overall (n = 44) . | Malawi (n = 30) . | South Africa (n = 8) . | Tanzania (n = 5) . | Thailand (n = 1) . |
|---|---|---|---|---|---|
| Age, median | 39 | 38.5 | 40.5 | 39 | 44 |
| Female, % | 66.0 | 74.0 | 62.5 | 40 | 0.0 |
| VL median, log copies/mL | 4.75 | 5.01 | 4.26 | 5.01 | 4.29 |
| CD4 median, cells/µL | 115 | 56 | 209 | 172 | 6 |
| First-line regimen | |||||
| d4T 3TC EFV | 5 | 0 | 5 | 0 | 0 |
| d4T 3TC NVP | 25 | 17 | 2 | 5 | 1 |
| TDF 3TC NVP | 3 | 3 | 0 | 0 | 0 |
| AZT 3TC EFV | 1 | 0 | 1 | 0 | 0 |
| AZT 3TC NVP | 10 | 10 | 0 | 0 | 0 |
| Time median on first-line, months | 36 | 39 | 22 | 54 | 32 |
Abbreviations: 3TC, lamivudine; ACTG, AIDS Clinical Trials Group; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine.
| Characteristics . | Overall (n = 44) . | Malawi (n = 30) . | South Africa (n = 8) . | Tanzania (n = 5) . | Thailand (n = 1) . |
|---|---|---|---|---|---|
| Age, median | 39 | 38.5 | 40.5 | 39 | 44 |
| Female, % | 66.0 | 74.0 | 62.5 | 40 | 0.0 |
| VL median, log copies/mL | 4.75 | 5.01 | 4.26 | 5.01 | 4.29 |
| CD4 median, cells/µL | 115 | 56 | 209 | 172 | 6 |
| First-line regimen | |||||
| d4T 3TC EFV | 5 | 0 | 5 | 0 | 0 |
| d4T 3TC NVP | 25 | 17 | 2 | 5 | 1 |
| TDF 3TC NVP | 3 | 3 | 0 | 0 | 0 |
| AZT 3TC EFV | 1 | 0 | 1 | 0 | 0 |
| AZT 3TC NVP | 10 | 10 | 0 | 0 | 0 |
| Time median on first-line, months | 36 | 39 | 22 | 54 | 32 |
| Characteristics . | Overall (n = 44) . | Malawi (n = 30) . | South Africa (n = 8) . | Tanzania (n = 5) . | Thailand (n = 1) . |
|---|---|---|---|---|---|
| Age, median | 39 | 38.5 | 40.5 | 39 | 44 |
| Female, % | 66.0 | 74.0 | 62.5 | 40 | 0.0 |
| VL median, log copies/mL | 4.75 | 5.01 | 4.26 | 5.01 | 4.29 |
| CD4 median, cells/µL | 115 | 56 | 209 | 172 | 6 |
| First-line regimen | |||||
| d4T 3TC EFV | 5 | 0 | 5 | 0 | 0 |
| d4T 3TC NVP | 25 | 17 | 2 | 5 | 1 |
| TDF 3TC NVP | 3 | 3 | 0 | 0 | 0 |
| AZT 3TC EFV | 1 | 0 | 1 | 0 | 0 |
| AZT 3TC NVP | 10 | 10 | 0 | 0 | 0 |
| Time median on first-line, months | 36 | 39 | 22 | 54 | 32 |
Abbreviations: 3TC, lamivudine; ACTG, AIDS Clinical Trials Group; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
